Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly
R J
RJ
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Small
T N
TN
Papadopoulos
E
E
Lucas
K
K
Lacerda
J
J
Koulova
L
L
D000208:Acute Disease; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D001402:B-Lymphocytes / Q000821:virology; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002472:Cell Transformation, Viral / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000628:therapy* / Q000821:virology; D006680:HLA Antigens; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000502:physiology; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host / Q000276:immunology; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000628:therapy* / Q000821:virology; D051381:Rats; D013601:T-Lymphocytes / Q000821:virology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014184:Transplantation, Homologous; D014764:Viral Proteins / Q000276:immunology; D017735:Virus Latency
D000956:Antigens, Viral; D006680:HLA Antigens; D014764:Viral Proteins